Medtronic PLC  

(Public, NYSE:MDT)   Watch this stock  
Find more results for MDT
77.32
+0.75 (0.98%)
May 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 76.47 - 77.44
52 week 58.32 - 79.50
Open 77.43
Vol / Avg. 0.00/4.77M
Mkt cap 110.19B
P/E 24.75
Div/yield 0.31/1.58
EPS 3.12
Shares 1.43B
Beta 1.10
Inst. own 83%
Jun 2, 2015
Q4 2015 Medtronic PLC Earnings Release - 9:30AM EDT - Add to calendar
Jun 2, 2015
Q4 2015 Medtronic PLC Earnings Call - 8:00AM EDT - Add to calendar
May 29, 2015
Medtronic PLC at Sanford C Bernstein Strategic Decisions Conference - 11:00AM EDT - Add to calendar
Mar 11, 2015
Medtronic Inc at Barclays Healthcare Conference - Webcast
Mar 3, 2015
Medtronic Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Jan '15) 2014
Net profit margin 22.63% 18.02%
Operating margin 33.07% 22.42%
EBITD margin - 33.33%
Return on average assets 8.34% 8.42%
Return on average equity 19.79% 16.08%
Employees 49,000 -
CDP Score - 81 D

Address

20 On Hatch, Lower Hatch Street
DUBLIN, 2
Ireland
+353-1-4381700 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Medtronic plc is a medical technology, services and solutions company. The Company offers its products to hospitals, physicians, clinicians and patients in over 160 countries. The Company’s portfolio includes surgical, respiratory and monitoring, and vascular therapies solutions along with a line of patient care products to alleviate pain, restore health and extend life for people. The Company operates in three segments: Cardiac and Vascular Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment manufactures and markets device-based medical therapies for Cardiac Rhythm Disease Management (CRDM), Coronary, Structural Heart and Endovascular. The Restorative Therapies Group segment manufactures and markets device-based medical therapies for Spine, Neuromodulation and Surgical Technologies. The Diabetes Group segment manufactures and markets device-based medical therapies for diabetes. Medtronic Inc is a wholly owned subsidiary of Medtronic plc.

Officers and directors

Omar Ishrak Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Gary L. Ellis Chief Financial Officer, Senior Vice President, Director
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Carol A. Surface Chief Human Resource Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Michael J. Coyle Executive Vice President, Group President - Cardiac and Vascular Group
Age: 51
Bio & Compensation  - Reuters
Hooman C. Hakami Executive Vice President and Group President of the Medtronic Diabetes Group
Age: 44
Bio & Compensation  - Reuters
Robert ten Hoedt Executive Vice President and President, EMEAC
Age: 53
Bio & Compensation  - Reuters
Christopher J. O'Connell Executive Vice President and Group President - Restorative Therapies Group
Age: 47
Bio & Compensation  - Reuters
Richard E. Kuntz M.D. Senior Vice President, Chief Scientific, Clinical and Regulatory Officer
Age: 57
Bio & Compensation  - Reuters
Bradley E. Lerman Senior Vice President, General Counsel, Corporate secretary, Director
Age: 57
Bio & Compensation  - Reuters
Geoffrey S. Martha Senior Vice President - Strategy and Business Development
Age: 44
Bio & Compensation  - Reuters